Bioventus Inc. (BVS) Stock

Healthcare · Medical Devices · Member of Other US Stocks

Bioventus Inc. (BVS) closed at USD 13.50 on 2026-10-14, a change of +94.5 % over the past year, with a market capitalization of USD 943.29M.

Bioventus Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Bioventus Inc. key figures

Previous close

USD 13.50 (2026-10-14)

1-year change

+94.5 %

Market cap

USD 943.29M

Enterprise value

USD 1.23B

P/E ratio (trailing)

17.71

P/E ratio (forward)

15.01

EPS (trailing)

0.78

EPS (forward)

0.92

PEG ratio

1.53

Price to book

4.13

Revenue growth

3.8 %

Earnings growth

327.3 %

Dividend per share (trailing)

0.00

Short ratio

6.34

Employees

950

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Bioventus Inc.

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Bioventus Inc. and compare it with other stocks.